Dupilumab

Where the papers sit

25 papers from the last 6 months study dupilumab directly · updated from PubMed 12 Oct 2026

• Atopic Dermatitis Treatment

  Atopic dermatitis treatment is being compared through long-term real-world response, safety, and growth outcomes for dupilumab versus upadacitinib. EASI trajectories and benefit-risk analyses favor individualized selection, while ocular events and microbiome changes recur as practical concerns. ANKFN1 and mast-cell activity suggest a route toward response biomarkers. Rare coccidioidomycosis and emerging cutaneous T-cell lymphoma keep infection surveillance and diagnostic caution open questions.

  9 papers · 36%

• Type 2 Inflammatory Disorders

  Type 2 inflammatory disease management is shifting toward steroid-sparing dupilumab use across severe asthma and related airway disorders. Real-world work tracks inhaled-corticosteroid de-escalation, lung function, chronic rhinosinusitis with nasal polyps, and COPD outcomes. Eosinophilia and ocular events recur as safety issues, with ocular risk compared directly against IL-5 inhibitors. Evidence in chronic spontaneous urticaria and checkpoint inhibitor–induced bullous pemphigoid extends the clinical scope, but remains case-series or cohort based.

  7 papers · 28%

• Type 2 Disease Outcomes

  Eosinophilic esophagitis and gastritis are moving toward biologic treatment, with dupilumab efficacy assessed against placebo, topical steroids, and proton pump inhibitors. Week-12 responses and infectious outcomes anchor the evidence, but real-world treatment patterns remain variable. Longer follow-up in prurigo nodularis supports durable benefit, while pediatric pharmacovigilance continues to map adverse-event signals. The shared direction is broader use of dupilumab in type 2 disease with closer safety monitoring.

  5 papers · 20%

• IL-4 and IL-13 Biology

  IL-4 and IL-13 blockade is being examined across atopic disease, asthma, transplant care, and pulmonary fibrosis. Seasonal cytokine profiling and registry data are refining patient characterization rather than establishing a single biomarker. Pediatric liver-transplant experience supports clinical feasibility in selected patients. Mechanistic work links benefit in fibrosis to disrupted macrophage–fibroblast crosstalk and IL4R/JAK/STAT signaling, but response determinants remain open.

  4 papers · 16%